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Oral drug delivery is the most widely applicable 
administration route among all other drug 
administration routes such as nasal, ophthalmic, rectal, 
transdermal, and parenteral routes. It has been explored 
for systemic delivery of drugs via pharmaceutical 
products of a different dosage form1. The majority of the 
pharmaceutical products designed for oral delivery are 
immediate release or conventional release systems for 
rapid drug absorption2. Conventional dosage forms have 
various limitations to deliver the dosage form via the oral 
route, such as poor patient compliance, increased chances 
of dose missing of a drug with a short half-life for which 
frequent administration is necessary3. 
In order to overcome the drawbacks of conventional 
drug delivery systems, several technical advancements 
have led to the development of a controlled drug delivery 
system that could revolutionize the method of 
medication and provide several therapeutic benefits4. 
Controlled drug delivery systems have been developed 
to control the rate of drug delivery, sustaining the 
duration of therapeutic activity and targeting the delivery 
of drugs to tissues5. Controlled drug delivery or modified 
drug delivery systems are conveniently divided into four 
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 Abstract 
This study aimed to improve the dissolution rate of aceclofenac and 
release the drug in a controlled manner over a period of 24 hours. 
Matrix tablets were prepared by direct compression method, using 
hydrophilic polymers (HPMC/guar gum). Matrix tablets were 
prepared by wet granulation method using different hydrophilic 
polymers (HPMC/guar gum). Tablets were evaluated for in vitro drug 
release profile in phosphate buffer with pH 6.8 (without enzymes). The 
thickness and hardness of prepared tablets were 3.23 ± 0.035 to 3.28 ± 
0.008 mm and 3.26 ± 0.115 to 3.60 ± 0.200 kg/cm2, respectively. The 
friability was within the acceptable limits of pharmacopoeial 
specifications (0.31 to 0.71%), which indicates the good mechanical 
strength of the tablets. Drug release was retarded with an increase in 
polymer concentration due to the gelling property of polymers. The in 
vitro drug release from the proposed system was best explained by 
Higuchi’s model, indicating that drug release from tablets displayed a 
diffusion-controlled mechanism. The results clearly indicate that guar 
gum could be a potential hydrophilic carrier in developing oral 
controlled drug delivery systems. Based on the study results, 
formulations F8 was selected as the best formulation. 
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categories: delayed release, sustained release, site-specific 
targeting, and receptor targeting6.  
A controlled drug delivery system is usually designed to 
deliver the drug at a particular rate. Safe and adequate 
blood levels are maintained for a period as long as the 
system continues to deliver the drug7. Controlled drug 
delivery usually results in substantially constant blood 
levels of the active ingredient compared to the 
uncontrolled fluctuations observed when multiple doses 
of quick releasing conventional dosage forms are 
administered to a patient8. 
The introduction of matrix tablets as the sustained release 
(SR) has given a breakthrough for novel drug delivery 
systems (NDDS) in pharmaceutical technology9. It 
excludes complex production procedures such as coating 
and palletization during manufacturing, and the drug 
release rate from the dosage form is controlled mainly by 
the type and proportion of polymer used in the 
preparations10. The hydrophilic polymer matrix is widely 
used for formulating an SR dosage form. Because of 
increased complications and expense involved in the 
marketing of new drug entities, it has focused greater 
attention on developing sustained release or controlled 
release drug delivery systems11. 
Matrix systems are widely used for sustained release. It is 
the release system that prolongs and controls the release 
of the dissolved or dispersed drugs12. A matrix is a well-
mixed mixture of one or more drugs and a gelling agent, 
such as hydrophilic polymers. The sustained release 
approach allows for therapeutically efficient 
accumulation in the systemic circulation over a more 
extended period, resulting in improved patient 
compliance13. 
Many SR oral dosage forms have been developed, 
including membrane-controlled systems, matrix with 
water-soluble/insoluble polymers or waxes, and osmotic 
systems. Recent research has concentrated on the 
designation of SR systems for poorly water-soluble 
drugs14. The lipid waxes and related materials prepare 
the lipid matrix. In this system, the active compound is 
contained in a hydrophobic matrix that remains intact 
during drug release15. 
The release of the active substance depends on the 
aqueous medium dissolving the conduit, which is 
released from the solids, forming a porous matrix of 
tortuous capillaries. The active substance dissolves in the 
aqueous medium and diffuses out of the matrix by way 
of the water-filled capillaries16. The materials used as 
matrix formers include hydrogenated vegetable oil, 
hydrogenated cottonseed oil, hydrogenated soy oil, 
microcrystalline wax, carnauba wax, as well as 
hydroxypropyl methylcellulose (HPMC)17. 
Aceclofenac is a potent inhibitor of the enzyme 
cyclooxygenase, which is involved in the production of 
prostaglandins18. The drugs inhibit the synthesis of the 
inflammatory cytokines interleukin (IL)-1 and tumor 
necrosis factor (TNF) and prostaglandin E2 (PGE2) 
production. Effects on cell adhesion molecular from 
neutrophils have also been noted. In vitro data indicate 
inhibition of cyclooxygenase (COX)-1 and 2 by 
aceclofenac in whole blood assays, with selectivity for 
COX-2 being evident19. 
Aceclofenac is a perfect applicant for a sustained release 
tablet. It reduces the frequency of drug administration 
and improves bioavailability, and increases patient 
compliance20.  Aceclofenac has a short biological half-life 
of 2-4 hours; thus, it does not show the pharmacological 
effect for a long time21. Sustained-release tablets have the 
properties to release slowly, and they maintain the 
bioavailability of drugs for a long time. Therefore, in this 
study, we made a sustained release tablet of aceclofenac 
and determined all in vitro parameters of sustained-
release tablets. 
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MATERIALS AND METHODS 
Materials 
The material used were aceclofenac (Sigma-Aldrich), 
HPMC K15M, Guar gum, lactose, polyvinylpyrrolidone 
(PVP) K-30, isopropyl alcohol (IPA), talc, magnesium 
stearate, phosphate buffer pH 6.8, HCl, distilled water, 
and KBr. The instruments used include melting point 
apparatus, water bath shaker, UV spectrophotometer 
(Labindia), Fourier Transform Infrared (FTIR) 
Spectroscopy (Shimadzu), sieve #10, #18, #40, digital 
analytical balance, micromeritics instrument, micrometer 
(Mitutoyo), Monsanto tablet hardness tester, Roche 
friabilator, and dissolution apparatus type 1 basket. 
Methods 
The study was divided into three stages: preformulation, 
granule preparation-evaluation, and tablet formulation-
evaluation. Each stage consists of several tests and 
evaluations. The method flow chart is presented in 
Figure 1. 
 
Figure 1. Flowchart for sustained release tablet preparation 
and evaluation parameters 
 
Physical appearance 
Aceclofenac powder was poured on light and dark 
backgrounds, and its physical appearance was observed. 
The results were compared with standard references22. 
Determination of melting point 
The melting point of the aceclofenac was determined by 
the capillary fusion method. A one-sided closed capillary 
was filled with drug and placed into the Remi’s melting 
point apparatus. The temperature at which solid drug 
converted into liquid was recorded and compared with 
standard references22. 
Solubility studies 
The solubility of Aceclofenac was tested in different 
solvents. The drug (50 mg) was dissolved in 10 ml of 
solvent in a 10 mL solubility bottle. The bottle was 
adequately covered with a lid and placed in the water 
bath shaker maintained at 37°C for 24 hours. Samples 
were taken manually and filter through 0.45 μm filter 
paper. The UV absorbance of the solution was recorded 
using a UV spectrophotometer after suitable dilutions at 
273.5 nm23. 
Compatibility study of drug and polymer (FTIR) 
The sample was mixed with a suitable amount of KBr 
and converted into pellets using KBr press at 15 tons 
hydraulic pressure. The IR scanning of samples was done 
in between 4000 and 400 cm-1 and spectrum observed for 
any occurrence and disappearance of characteristic drug 
peak and compared with the standard references23. 
Tablet preparation 
The tablet formulation was carried out by varying the 
matrix formers: HPMC and Guar gum. In total, there 
were nine formulas for tablets, as shown in Table I. The 
corresponding amounts of the drug were accurately 
weighed and passed through the #40 sieve. The 
corresponding amounts of polymers (HPMC/Guar 
gum) and lactose were accurately weighed, screened 
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through screen #40. The screened mass was transferred 
into a clean and dry mortar and mixed gently for 5 
minutes. Alcoholic solution (IPA) of PVP K 30 (5% w/v) 
was added to the powder mixture blended to form a wet 
mass. The wet mass was passed through sieve no. #10 
and the resulting granules were placed on a tray for 
drying into the oven at 50°C for 10 minutes. The dried 
granules were passed through sieve no—#18. The 
corresponding magnesium stearate and talc were 
accurately weighed and then mixed with dried granules 
for 3 minutes. The granules were compressed into tablets 
using a single station hand operated tablet compression 
machine, and the tablets were collected23. 





F1 F2 F3 F4 F5 F6 F7 F8 F9 
Aceclofenac 200 200 200 200 200 200 200 200 200 
HPMC 50 100 150 200 - - - - 100 
Guar gum - - - - 50 100 150 200 100 
Lactose 200 150 100 50 200 150 100 50 50 
PVP K30 25 25 25 25 25 25 25 25 25 
IPA q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. 
Talc 20 20 20 20 20 20 20 20 20 
Mg Stearate 5 5 5 5 5 5 5 5 5 
 
Determination of bulk density 
Bulk density was defined as the mass of the powder 
divided by the bulk volume and expressed as g/cm3. It 
depends upon particle size distribution, particle shape, 
and particle adhere. Apparent bulk density was 
determined by pouring the blend into a 10 mL graduated 
cylinder and calculated based on the equation as 
reported by Yasmin et al24. 
Determination of tapped density 
The measuring cylinder containing a known mass of 
powder blend was tapped 100 times using density 
apparatus. The minimum volume occupied by the 
powder in the cylinder was measured. The tapped 
density was calculated based on the equation as reported 
by Yasmin et al24. 
 
Determination of angle of repose 
The angle of repose (θ) was determined using the funnel 
method. Briefly, the powder blend was poured through 
a funnel that can be raised vertically until a maximum 
cone height was obtained. The radius of the heap was 
measured, and the angle of repose was calculated based 
on the equation as reported by Yasmin et al24. The values 
of angle of repose indicating flow properties have been 
recommended as <25 indicating excellent flow, 25-30 
indicating good flow, 30-40 indicating passable, and >40 
indicated the very poor flow. 
Determination of compressibility index 
Determination of compressibility index was the simplest 
way to measure the flow property of powder to 
determine its compressibility. Compressibility index 
indicates the ease with which a material could induce 
flow, which was calculated using the equation as 
reported by Yasmin et al24. The values of compressibility 
index indicating flow properties have been 
recommended as <12 indicating excellent flow, 12 – 16 
indicating good flow, 18 – 21 indicating fair to passable, 
25 – 35 indicating poor, 33 – 38 indicating very poor, and 
>40 indicated the extremely poor flow. 
Determination of Hausner’s ratio 
Hausner’s ratio was an indirect index of ease of powder 
flow. Density determinations were used to calculate the 
Hausner’s ratio using the equation as reported by 
Yasmin et al24. Lower Hausner’s ratio (<1.25) indicates 
better flow properties than higher ones (>1.25). 
Examination of tablet appearance 
Twenty tablets of each formulation were randomly taken 
and examined to check any physical or surface 
roughness in the tablets. 
Determination of tablet thickness 
Tablet thickness was an essential parameter in 
reproducing appearance and also in counting by suing 
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filling equipment. Many tablet filling/packaging 
equipment utilizes the uniform thickness of the tablets as 
a counting mechanism25. In the present study, 10 tablets 
were randomly selected, and their thickness was 
recorded using a micrometer. 
Determination of uniformity of weight 
The weight variation test would be a satisfactory method 
of determining the drug content uniformity. USP 
procedure for uniformity of weight was followed. The 
allowed weight variation limits were 10%, 7.5%, and 5% 
for tablets having weight 130 mg or less, 130-324 mg, and 
>324 mg, respectively26. Briefly, 20 tablets were taken and 
weighed individually and collectively using a digital 
analytical balance. The average weight of one tablet was 
determined from the collective weight. 
Determination of tablet hardness 
The hardness of the tablet was defined as the force 
applied across the diameter of the tablet to break it. The 
resistance of a tablet to chipping, abrasion, or breakage 
under the condition of storage, transportation, and 
handling before use depends on its hardness or 
strength27. For the determination of tablet hardness, 10 
tablets from each batch were randomly selected, and 
hardness was determined using Monsanto tablet 
hardness tester. 
Determination of tablet friability 
The friability of the prepared tablets was determined 
using Roche friabilator. This device subjects the tablets to 
the combined effect of abrasions and shock in a plastic 
chamber revolving at 25 rpm and dropping the tablets at 
the height of 6 inches in each revolution. Previously 
weighed, 20 tablets were placed in the friabilator and 
subjected to 100 revolutions. Tablets were de-dusted 
using a soft muslin cloth and re-weighed. The percentage 
friability was determined using the equation as reported 
by Ahmed et al28. 
Determination of drug content 
Six tablets from each batch were weighed and finely 
powdered using a clean and dry mortar and pestle. 
Powder equivalent to the weight of one tablet was 
transferred to a 100 mL volumetric flask and shaken with 
60 mL of phosphate buffer for 10 minutes. The volume of 
the resulting solution was made to 100 mL and kept for 
24 hours. After 24 hours, the content was filtered. An 
aliquot of 1.0 mL from the filtrate was diluted to 100 mL 
with phosphate buffer in a volumetric flask, and then 
further 1 mL from this solution was diluted up to 10 mL 
phosphate buffer in a 10 mL volumetric flask29. The 
sample was analyzed by a UV spectrophotometer at 
273.5 nm. 
Determination of in vitro dissolution profile 
The in vitro dissolution studies were carried out in the 
USP tablet dissolution test apparatus, type 1 (basket). As 
much as 900 mL of phosphate buffer (without enzymes) 
was used as a dissolution medium. Dissolution studies 
were carried out for 24 hours. The temperature of the 
dissolution medium was maintained at 37±0.5°C. The 
paddle was rotated at 75 rpm. Sample (5 mL) was 
withdrawn data predetermined interval for 24 hours. 
Complete sink condition was maintained by replacing 
the same volume of fresh dissolution medium after each 
sampling. The samples were diluted to a suitable volume 
with phosphate buffer, and the absorbance was recorded 
at 273.5 nm using a UV spectrophotometer23. 
 
RESULTS AND DISCUSSION 
Physical appearance 
Pure aceclofenac used in the form of a faded white 
crystalline powder as stated in the physical identification 
results of the drug sample was identical to the reference 
standard. These results confirm the identity of 
aceclofenac. 
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Determination of melting point 
The melting point value observed was 149ºC. These 
values match the values mentioned in standard 
references (149-153ºC)22, confirming that the drugs used 
in this study were in their pure form. 
Solubility studies 
Aceclofenac has better solubility in phosphate buffer and 
does not have good solubility in distilled water and 0.1 N 
HCl, as presented in Table II. 
Table II. Solubility of aceclofenac 
Solvent Solubility (mg/mL) Remark 
Distilled water 0.187 practically 
insoluble 
0.1N HCl 0.283 practically 
insoluble 
Phosphate buffer 0.841 slightly 
soluble 
 
Compatibility study of drug and polymer (FTIR) 
The peaks at 3319 cm-1 and 3267 cm-1 in the FTIR 
spectrum of aceclofenac (Figure 2) are associated with 
OH hydrogen bonds. This peak at 2970 cm-1 was due to 
the aromatic stretching of NH. The stick peak character 
near 2937 cm-1 may be due to the stretching of the CH 
from the CH groups. The peak at 1750 cm-1 indicates the 
presence of carboxylic acids in the compound. The peaks 
at 1589 cm-1, 1577 cm-1, and 1508 cm-1 indicate a stretch of 
the C = C ring. The overall functional group analysis is 
presented in Table III. 
Table III. FTIR spectrum of aceclofenac and its functional 
groups 
Peak (cm-1) Remark 
3319 OH hydrogen bonding 
3267 OH hydrogen bonding 
2970 NH aromatic stretching 
2937 CH stretching 
1750 C=O stretching 
1589 C=C stretching 
1577 C=C stretching 
1508 C=C stretching 
 
Micromeritic properties 
The flow property of granules was estimated based on 
different micromeritic properties. The bulk density and 
tapped density were determined using USP bulk density 
apparatus, and the results are represented in Table IV. 
The bulk density and tapped density were found to be 
almost similar, indicating similar flow properties. The 
differences in bulk density and tapped density were 
minimal, indicating that the change volume is 
significantly less even after 100 tapping30, which confirms 
uniform particle size range and reproducibility in drug. 
Hausner’s ratio is related to inter-particle friction. 
Hausner’s ratio is indirect measures of bulk density, size, 
and shape, surface area, moisture content, and 
cohesiveness of granules. A higher Hausner’s ratio and 
more fine particles indicate greater cohesion between 
particles, while a low range of Hausner’s ratio indicates 
good flowability. The desirable value of Hausner’s ratio 
is <1.25 for a good flow of materials. The Hausner’s ratio 
of granules was determined and found to be in the range 
of 1.12±0.040 to 1.19±0.035. An increase in Hausner’s ratio 
is due to an increase in granule size, and this might be due 
to increased void space between the particles31. 
It is well known that particle size and shape influence 
flowability. The fine particles (<100 mm) tend to be more 
cohesive and therefore less free-flowing, whereas larger 
denser particles tend to be free-flowing. The rougher and 
more irregular the surface of the particles, the higher will 
be the angle of repose32. In the present study, the angle of 
repose increased from 26.78±0.600 to 30.60±0.566° as the 
particle size increased, indicating the decrease in 
flowability of granules33. This is also supported by the 
results of Hausner’s ratio study. 
A high compressibility index is indicative of the tendency 
to form bridges between the particles. The smaller the 
compressibility index, the better the flow properties; for 
example, a value of 5 to 15 indicates excellent, 12 to 18 
good, 19 to 21 fair and 22 to 35 poor, 36 to 40 very poor, 
and >40 extremely poor flow34. The results show a 
compressibility index in the range of 10.93±0.150 to 
14.76±0.462, which indicates excellent flow property. 
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Figure 2. FTIR spectrum of aceclofenac 
 































































































































































Post compression results 
The tablets were evaluated for weight variation, 
thickness, hardness, friability drug content, and in vitro 
drug release profiles. Weight variation data indicates no 
significant difference in individual tablet weight from the 
average weight (500.333±0.577 to 502.33±0.577). Tablet 
hardness was observed within the range of 3.26±0.115 to 
3.60±0.200 kg/cm2. A uniform thickness of the tablets 
was observed in the range of 3.23±0.004 to 3.28±0.008. The 
Friability of all the formulations was below 1%, indicating 
good mechanical strength of the tablets (Table V). From 
the in vitro drug release data, it was clear that the drug 
release was decreased with an increase in polymer 
concentration. The drug release was found to occur 
through a swelling process35. 
Table VI was to find out the mechanism of drug release, 
and also to verify the fact that whether diffusion was 
Fickian or non-Fickian. The in vitro dissolution data of all 
the batches was plotted according to the Peppas’ 
equation, in which cumulative log percentage of drug 
release was plotted against log time. From the kinetic 
data, it was evident that the drug release was found to 
follow Peppas’ model for all the formulations, and the 
release was diffusion controlled. The calculated slope 
values of Peppas’ equations gave a value close to 1 but 
less than 1, which confirmed that the release mechanism 
of aceclofenac from the hollow beads was Fickian 
diffusion with swelling in both the media36. From Table 
VII, it was clear that all the formulations had ‘n’ values 
greater than 0.5 and less than 1, which confirms that the 
release mechanism of aceclofenac from the prepared 
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matrix tablets in phosphate buffer was Fickian diffusion 
with swelling37. 
Table V. Post compression results of aceclofenac sustained 




















































































































Table VI. In vitro drug release of aceclofenac from sustained 




F1 F2 F3 F4 F5 F6 F7 F8 F9 


















































































































































































































































































































































































































































































































































































































































In this work, an attempt was made to formulate and 
evaluate sustained release matrix tablets of aceclofenac to 
maintain the plasma drug concentration constant for the 
whole day. It also helps in decreasing the dosing 
frequency by which the patient compliance increases. 
Aceclofenac has a very short half-life (t½ 2-4 hours), so in 
conventional tablets, aceclofenac dosing frequency is 
more. Drugs with a short half-life cannot maintain the 
plasma drug concentration at the therapeutic levels for a 
more extended period38. Thus, to decrease the dosing 
frequency and increase patient compliance, sustained 
release matrix tablets were formulated. 
In the preformulation studies, aceclofenac was 
characterized based on its physicochemical properties by 
determining melting point, solubility, UV spectroscopy, 
and FTIR studies. There were no physical changes after, 
and also no significant interaction of drug with polymers 
was observed in the UV and FTIR analysis after four 
weeks as the drug and polymers were compatible and 
thus were finalized to use in the formulation of sustained-
release tablets29. Quality parameters such as tablet 
diameter, thickness, hardness, friability, and dissolution 
profile were evaluated. The best release profile was 
obtained from tablets containing Guar gum matrix 
former without HPMC in an equivalent proportion to the 
drug (F8). The best-selected tablet formulation had 
friability 0.68%, hardness 3.40±0.200 kg/cm2, and 
99.8±0.05 drug release after 24 hours of the dissolution 
study. 
Table VII. Estimated values of diffusional exponent and 
correlation coefficient from the dissolution data of 













F1 0.9711 0.9118 0.9973 0.9813 0.612 
F2 0.9709 0.8666 0.9964 0.9674 0.598 
F3 0.9687 0.8412 0.9959 0.9784 0.632 
F4 0.9770 0.8204 0.9957 0.9809 0.618 
F5 0.9771 0.8070 0.9934 0.9712 0.545 
F6 0.9718 0.8296 0.9950 0.9778 0.625 
F7 0.9770 0.8066 0.9964 0.9840 0.559 
F8 0.9696 0.8079 0.9947 0.9824 0.573 
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CONCLUSION 
In this study, the prepared matrix aceclofenac tablet 
showed significant drug release property. It maintains 
the constant concentration for a long time means that it 
increases the half-life and bioavailability of the drug. 
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